Michigan is currently home to 2237 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Ann Arbor, Detroit, Grand Rapids and Kalamazoo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
Recruiting
This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the safety and efficacy of AGN-193408 SR in participants with open-angle glaucoma or ocular hypertension
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: Fraser Eye Care Center /ID# 267100, Fraser, Michigan
Conditions: Open-angle Glaucoma, Ocular Hypertension
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Recruiting
This phase II trial studies how well ramucirumab and paclitaxel or the FOLFIRI regimen (leucovorin calcium, fluorouracil, and irinotecan hydrochloride) work in treating patients with small bowel cancers that have spread extensively to other anatomic sites (advanced) or are no longer responding to treatment (refractory). Ramucirumab is a monoclonal antibody that attaches to and inhibits a molecule called VEGFR-2. This may restrain new blood vessel formation therefore reducing nutrient supply to t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: Hickman Cancer Center, Adrian, Michigan
Conditions: Metastatic Small Intestinal Adenocarcinoma, Stage III Small Intestinal Adenocarcinoma AJCC v8, Stage IIIA Small Intestinal Adenocarcinoma AJCC v8, Stage IIIB Small Intestinal Adenocarcinoma AJCC v8, Stage IV Small Intestinal Adenocarcinoma AJCC v8
AERA Pediatrics Registry
Recruiting
Prospective, multi-center, observational, real-world evidence data collection registry to confirm the continued clinical performance of the AERA® device in pediatric patients
Gender:
ALL
Ages:
18 years and below
Trial Updated:
07/08/2025
Locations: Michigan Pediatric ENT Associates, West Bloomfield, Michigan
Conditions: Dysfunction of Eustachian Tube
Physical Activity and Percussive Massage Therapy for Reducing Pain in Older Women
Recruiting
Over 60% of women aged 65 and older suffer from pain, yet this group is underrepresented in research. Physical activity and percussive massage therapy may help manage pain, but both require consistent engagement, making long-term participation challenging for most people. Self-monitoring could improve adherence to these pain management efforts, but the optimal strategies for self-monitoring remain unknown. This is a a 2x2 factorial randomized controlled trial in older women (N = 108) to determi... Read More
Gender:
FEMALE
Ages:
65 years and above
Trial Updated:
07/08/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Pain, Chronic
Hemodynamics After Resistance Training
Recruiting
Women's blood vessel health gets worse after menopause, or "the change of life". Some women exercise less during menopause. Exercise can improve blood vessel health. The investigators want to know if resistance exercise, like lifting weights, can improve blood vessel health in women who are just starting menopause. The investigators also want to know if lifting weights can improve mood, sleep, and quality of life in women going through menopause. The investigators will have two groups of women f... Read More
Gender:
FEMALE
Ages:
Between 40 years and 60 years
Trial Updated:
07/08/2025
Locations: University of Michigan School of Kinesiology, Ann Arbor, Michigan
Conditions: Perimenopause
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)
Recruiting
The primary purpose of this study is to evaluate the efficacy, safety, and tolerability of IMVT-1402 in participants with Cutaneous Lupus Erythematosus. The study will consist of 3 periods: Period 1: eligible participants will be randomized 1:1 to IMVT-1402 or placebo SC QW for 12 weeks. Period 2: participants who completed Period 1 will receive IMVT-1402 SC QW for 14 weeks. Period 3: after completion of Period 2, participants will be re-randomized 1:1 to blinded IMVT-1402 SC QW for 26 weeks... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Site Number - 1003, Saint Clair Shores, Michigan
Conditions: Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Safety and Efficacy of VDPHL01 in Males With AGA
Recruiting
This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA). AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablet is an investigational oral drug to treat male pattern baldness. This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, mont... Read More
Gender:
MALE
Ages:
Between 18 years and 65 years
Trial Updated:
07/08/2025
Locations: Site 68, Clinton Township, Michigan
Conditions: Androgenetic Alopecia, AGA, Male Pattern Baldness
FITting Non-invasive Tests in Lynch Syndrome Surveillance
Recruiting
The purpose of this clinical study is to evaluate the accuracy of the fecal immunochemical test (FIT) in comparison to colonoscopy in patients with Lynch Syndrome (LS) who are undergoing colonoscopy surveillance.
Gender:
ALL
Ages:
Between 20 years and 75 years
Trial Updated:
07/08/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Colorectal Cancer
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
Recruiting
A Phase 1 First-in-Human study of YL217 in Patients with Advanced Solid Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Karmanos Cancer Institute, Detroit, Michigan
Conditions: Advanced Solid Tumor
Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases
Recruiting
This is an open-label, single dose, single arm, multicenter Phase 2b study to establish the imaging performance of RAD101 PET in participants who are ≥ 18 years of age and with suspected recurrent brain metastases from solid tumors. The study consists of a 4-week Screening Period, a 3-day Imaging and Safety Follow-Up Period, and a Data Collection Period of up to 6 months. Participant eligibility will be determined during the Screening Period and eligible participants will be enrolled in the stu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Brain Metastases from Solid Tumors
Treatment of Moderate to Severe Refractory Crohn's Disease
Recruiting
This research study is testing an investigational research product called TRX103 as a possible treatment for individuals suffering from Crohn's Disease (CD). The primary purpose of this study is to learn how safe and effective different doses of TRX103 are when administered to individuals with CD.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/08/2025
Locations: University of Michigan, Ann Arbor, Ann Arbor, Michigan
Conditions: Crohns Disease
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Recruiting
The goal of this clinical trial is to learn if KQB365 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB365. The main questions it aims to answer are: * What is the safe dose of KQB365 by itself or in combination with cetuximab? * Does KQB365 alone or in combination with cetuximab decrease the size of the tumor? * What happens to KQB365 in the body? Participants will: * Receive KQB365 infusion weekly alone or in combination with cetuximab * Visit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: START Midwest, Grand Rapids, Michigan
Conditions: KRAS G12C Mutation, KRAS G12S Mutation, Solid Tumor Malignancies, CRC (colorectal Cancer)